(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 May 2003 (22.05.2003)

PCT

(10) International Publication Number
WO 03/041722 A1

(51) International Patent Classification[7]: A61K 31/7024, A61P 9/10

(21) International Application Number: PCT/EP02/12482

(22) International Filing Date:
7 November 2002 (07.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01204323.8 13 November 2001 (13.11.2001) EP

(71) Applicants *(for all designated States except US)*: **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). **SANOFI-SYNTHELABO** [FR/FR]; 174, avenue de France, F-75635 Paris Cedex 13 (FR).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **LENSING, Anthonie, Wilhelmus, Arnold** [NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL).

(74) Agent: **HOGENBIRK, M.**; P.O. Box 20, NL-5340 BH Oss (NL).

(81) Designated States *(national)*: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, TT, UA, US, UZ, VN, YU, ZA.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/041722 A1

(54) Title: USE OF SPECIFIC DOSE OF FONDAPARINUX SODIUM FOR THE TREATMENT OF ACS

(57) Abstract: The invention relates to the use of a dose of 2.5 mg of the pentasaccharide methyl O-(2-deoxy-2-sulfoamino-6-O-sulfo-α-D-glucopyranosyl)-(1-4)-O-(β-D-glucopyranosyl uronic acid)-(1-4)-O-(2-deoxy-2-sulfoamino-3,6-di-O-sulfo-α-D-glucopyranosyl)-(1-4)-O-(2-O-sulfo-α-L-idopyranosyl uronic acid)-(1-4)-2-deoxy-2-sulfoamino-6-O-sulfo-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of Acute Coronary Syndromes (ACS).